Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05882253 · ClinicalTrials.gov registry record · NA
Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
A NA study of Prostate Cancer, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- NA
- Development phase
- 225
- Enrollment target
- 1
- Study location
NCT05882253: Recruiting NA study of Prostate Cancer, sponsored by University of California, San Diego.
NCT05882253 is a NA study of Prostate Cancer that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 225 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05882253, a NA study of Prostate Cancer, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- NA
- Development phase
- 225 participants
- Enrollment target
- 1
- Study location
Study Summary
The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.
Primary Outcome
Radiologists will report a standard Prostate Imaging, Reporting, and Data System (PI-RADS) and document the RSM values associated with each lesion. Change in value will be reported from baseline to routine biopsy follow-up.
Conditions Studied
Interventions
- OTHER Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI)
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2023-12-04 |
| Est. Completion | 2028-04 |
| Phase | NA |
What NCT05882253 shows while recruiting
NCT05882253 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI) is the first listed.
NCT05882253 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05882253 about?
NCT05882253 is a clinical study titled "Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)". The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy.
What is the current status of trial NCT05882253?
This trial is currently recruiting. It is a NA study. The enrollment target is 225 participants. The study started on 2023-12-04. Estimated completion is 2028-04.
What conditions does trial NCT05882253 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05882253?
The interventions under investigation include: Restricted Spectrum Imaging-Magnetic Resonance Imaging (RSI-MRI) (OTHER).
Who is sponsoring clinical trial NCT05882253?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05882253 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05882253's enrollment target sits among peer trials
225 201st of 735 higher than 534 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Health Literacy in African-American Prostate Cancer Patients
RECRUITING · NA
-
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
RECRUITING · NA
-
Diffusion Basis Spectrum Imaging of the Prostate
RECRUITING · NA
-
Micro-UltraSound In Cancer - Active Surveillance
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
SBRT Boost for Unfavorable Prostate Cancer'
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI